Cidara Therapeutics Inc Cash Flow Conversion Efficiency
Cidara Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Cidara Therapeutics Inc (CDTX) has a cash flow conversion efficiency ratio of -0.096x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.62 Million) by net assets ($422.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Cidara Therapeutics Inc (2013–2024)
Cash flow conversion efficiency of Cidara Therapeutics Inc from 2013 to 2024. This chart illustrates how Cidara Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cidara Therapeutics Inc (CDTX) share price today for real-time trading data and today's change.
Cidara Therapeutics Inc Cash Flow Conversion Ratio Explained
Cidara Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Cidara Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cidara Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Cidara Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Gold Inc
TO:NGD
|
0.175x |
|
IDFC First Bank Limited
NSE:IDFCFIRSTB
|
-0.483x |
|
Vornado Realty Trust
NYSE:VNO
|
0.005x |
|
NKT A/S
CO:NKT
|
0.036x |
|
RATIONAL UN.ADR 1/ 1/20
F:RAA1
|
0.096x |
|
Shenzhen Fastprint Circuit Tech Co Ltd
SHE:002436
|
0.022x |
|
SODEXO S.A. ADR/ 1/5 EO 4
F:SJ70
|
N/A |
|
Apar Industries Limited
NSE:APARINDS
|
0.031x |
Annual Cash Flow Conversion Efficiency for Cidara Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Cidara Therapeutics Inc from 2013 to 2024. Review CDTX free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $163.31 Million | $-176.53 Million | -1.081x | -139.56% |
| 2023-12-31 | $-8.21 Million | $-22.43 Million | 2.732x | +38.55% |
| 2022-12-31 | $-14.44 Million | $-28.47 Million | 1.972x | +268.61% |
| 2021-12-31 | $21.57 Million | $-25.23 Million | -1.170x | +76.97% |
| 2020-12-31 | $10.71 Million | $-54.41 Million | -5.078x | -573.37% |
| 2019-12-31 | $37.84 Million | $-28.53 Million | -0.754x | +21.35% |
| 2018-12-31 | $59.14 Million | $-56.70 Million | -0.959x | -14.78% |
| 2017-12-31 | $59.74 Million | $-49.91 Million | -0.835x | -85.22% |
| 2016-12-31 | $88.18 Million | $-39.77 Million | -0.451x | -80.54% |
| 2015-12-31 | $103.91 Million | $-25.96 Million | -0.250x | +31.62% |
| 2014-12-31 | $21.10 Million | $-7.71 Million | -0.365x | -148.74% |
| 2013-12-31 | $-1.40 Million | $-1.05 Million | 0.750x | -- |
About Cidara Therapeutics Inc
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are funga… Read more